Therapeutics Uses of Psychedelics in patients with psychiatric disorders A Systematic Review

Abstract

The impact of psychedelic treatment on patients
suffering from psychiatric diseases like depression,
anxiety, post-traumatic psychiatric disorder (PTSD),
and existential distress related to cancer has become
very intriguing to psychiatrists in the modern era.
Serotonergic psychedelics include Lysergic acid
diethylamide (LSD), psilocybin, mescaline, ayahuasca,
and methylene-deoxy methamphetamine (MDMA)
which act agonistically on 5-hydroxytryptamine type 2-
A (5-HT2A) receptors. Psychedelics produce a wide
range of effects, based on varying sites of 5-HT2a
receptors, including changes in consciousness,
perception, mood, and behaviour. Psychedelics can lead
to both good and bad trips depending on the dose and
environment in which it is taken. We used systematic
approach by strictly following Preferred Reporting Items
for Systematic Reviews and Meta-analysis (PRISMA)
2020 guidelines. Data is extracted from pub med using
mesh strategy, and from google scholar and science
direct by using keywords. 10 review articles are selected
by using quality appraisal tools. The purpose of this
paper is to highlight the mechanism of action and role
of psychedelics in patients with mental health disorders.
In this review, we discussed the effective models of
neurodynamical changes produced by psychedelics, and
we also show that these substances can be used as a
potential treatment option for psychiatric patients.
Psychedelics have shown effective improvement in
psychiatric diseases in many pilot studies and
randomized controlled trials. There is still a debate
going on about which models best suggest their role in
the field of psychiatry.